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BOOK REVIEWS
The High Cost of Prescription Drugs:
The Price of Success?
H. Jeffrey Lawrence, M.D.*
The Big Fix: How the Pharmaceutical Industry Rips Off American Consumers.
By Katharine Greider. New York: PublicAffairs, 2003. Pp. 189.
Magic Cancer Bullet: How a Tiny Orange Pill Is Rewriting Medical History.
By Daniel Vasella with Robert Slater. New York: HarperBusiness, 2003. Pp.
258.
Two recent books provide radically different perspectives on the
pharmaceutical industry. The Big Fix by Katharine Greider' is squarely in
the muckraking tradition of Jessica Mitford, while the Magic Cancer Bullet
by Daniel Vasella 3 with Robert Slater is a business insider's view on modern
drug development. The Big Fix's subtitle-"How the Pharmaceutical
Industry Rips Off American Consumers"-captures its theme. By contrast,
Dr. Vasella develops the notion that modern drug development is
* Staff hematologist and former chair of the Bioethics Committee, Veterans Affairs
Medical Center, San Francisco, and Professor of Medicine in the Division of
Hematology/Medical Oncology at the University of California, San Francisco. The author
wishes to thank Brianne Gorod and Bonnie Pau for their assistance in editing this Book
Review.
1. KATHARINE GREIDER, THE BIG Fix: HOW THE PHARMACEUTICAL INDUSTRY RIPS OFF
AMERICAN CONSUMERS (2003).
2. For one example ofJessica Mitford's investigative work on the American funeral
industry, see JESSICA MITFORD, THE AMERICAN WAY OF DEATH (1963).
3. DANIEL VASELLA WITH ROBERT SLATER, MAGIC CANCER BULLET: HOW A TINY ORANGE
PILL IS REWRITING MEDICAL HISTORY (2003).
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incredibly complex and expensive, and drug companies take big risks that
need to be rewarded with big profits. While opposite in viewpoint, the
books share key characteristics. Both are short tomes targeting the lay
public. Both put a sharp focus on the issues of fair marketing and pricing
practices for prescription drugs. And, by ignoring the potential of
physicians to serve as agents of change, both fail to provide concrete steps
to alleviate the problem of prescription drug costs in America.
Much of what is covered in Greider's The BigFix, in eight chapters with
titles such as "Drugs R Us" and "Patent Shenanigans," is old territory-the
rapid rise in expenditures on prescription drugs in the United States, the
high profits of pharmaceutical firms, questionable patent manipulations,
aggressive marketing practices to physicians and the general public, and
the arcane pricing structure of pharmaceuticals. Many of the issues
discussed are important and compelling. There is little question that the
cost of medication is putting a heavy economic burden on elderly and
poor Americans, by some estimates consuming fourteen percent of the
average Social Security benefit.4 The common practice of developing "me-
too" drugs-with high price tags but only modest improvements in
convenience and/or toxicity-are described. 5 Greider discusses the
byzantine pricing practices of American pharmaceutical companies, with
consumer costs that drive the elderly to take bus trips to Canada for
cheaper medicines.
Perhaps the most critical ethical issue concerning the pharmaceutical
company relates to their marketing practices. Greider cites estimates that
the drug industry devotes one-quarter to one-third of its sales dollars to
marketing,7 amounts that may exceed the costs of research and
development. Like other consumer advocates, she finds these expenditures
excessive and largely responsible for the high cost of prescription drugs.
However, the pharmaceutical industry has persistently disputed these
estimates," and it is difficult, if not impossible, to find firm figures to
support either position. That being said, it is hard to believe that
4. Frank Davidoff, The Heartbreak of Drug Pricing, 134 ANNALS INTERNAL MED. 1068
(2001).
5. GREIDER, supra note 1, at 47-48.
6. Id. at 22-23.
7. Id. at 64.
8. See, e.g., Melody Petersen, Increased Spending on Drugs Is Linked to More Advertising,
N.Y. TIMES, Nov. 21, 2001, at CI (noting that "[t] he big drug companies ... objected" to a
study suggesting a link between advertising and the high cost of prescription drugs and
"said that their research showed no direct link between advertising and rising drug
expenses").
IV: 1 (2004)
HeinOnline  -- 4 Yale J. Health Pol'y L. & Ethics 166 2004
3
Lawrence: The High Cost of Prescription Drugs: The Price of Success?
Published by Yale Law School Legal Scholarship Repository, 2004
BOOK REVIEW-LAWRENCE
marketing costs cannot be reduced substantially, given that U.S. consumers
paid in excess of $145 billion in 2000 on prescription drugs!'
So why does the pharmaceutical industry devote such large sums of
money to advertising? Drug companies are not foolish, and they would not
spend billions of dollars on marketing if the medications sold themselves.
The medical literature bears out Greider's contention that meetings with
drug representatives and the provision of free samples do influence the
prescribing practices of physicians and the likelihood that they will request
that a new drug be added to their hospital formulary.' ° She also points out
that even young idealistic doctors in training are susceptible to the
pharmaceutical industry's direct marketing practices, which include giving
physicians gifts of expensive meals, books, medical equipment, and even
luggage and resort vacations." The Pharmaceutical Research and
Manufacturers of America (PhRMA) recently adopted a new Code on
Interactions with Healthcare Professionals, which significantly limits gift-
giving and entertainment to physicians, but the code is purely voluntary.' 2
Hospitals, HMOs, and many medical professional organizations have also
adopted stricter codes of ethics that impose limits on the interactions
between health care workers and pharmaceutical representatives. 3 But
much more could be done. These new codes do not address the issue of
direct advertising to consumers on television, radio and magazines.
Patients do go to their doctors and ask for the "purple pill" even if they do
not know what medical conditions it treats. If large medical organizations
and HMOs lobbied government and industry to end direct advertising to
the public, direct marketing could be severely curtailed.
What should drive the proper selection of prescription medicines if
9. Davidoff, supra note 4.
10. Lisa D. Chew et al., A Physician Survey of the Effect of Drug Sample Availability on
Physicians'Behavior, 15J. GEN. INTERNAL MED. 478 (2000); Mary-Margaret Chren & C. Seth
Landefeld, Physicians' Behavior and Their Interactions with Drug Companies A Controlled Study of
Physicians Who Requested Additions to a Hospital Drug Formulary, 271 JAMA 684 (1994); Marilyn
Y. Peay & Edmund R. Peay, The Role of Commercial Sources in the Adoption of a New Drug, 26
SOC. SC. MED. 1183 (1988).
11. Michael A. Steinman et al., Of Principles and Pens: Attitudes and Practices of Medicine
Housestaff Toward Pharmaceutical Industry Promotions, 110 AM.J. MED. 551 (2001).
12. Press Release, PhRMA, PhRMA Adopts New Marketing Code (Apr. 19, 2002),
http://www.phrma.org/mediaroom/press/releases/19.04.2002.390.cfm.
13. Gifts to Physicians from Industry, 265 JAMA 501 (1991); Susan L. Coyle, Physician-
Industry Relations Part 1: Individual Physicians, 136 ANNALS INTERNAL MED. 396 (2002); Susan
L. Coyle, Physician-Industry Relations Part 2: OrganizationalIssues, 136 ANNALS INTERNAL MED.
403 (2002).
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advertising is not to be trusted? Modern medical education has
promulgated the paradigm of evidence-based medicine. 4 In this model,
standards of therapy are derived from hard clinical science in the form of
well-designed controlled trials that are sufficiently powered to provide
convincing statistical evidence that one treatment is superior to another. In
an ideal world, all medical decisions would be based on such evidence. The
"winning" drug would be chosen by unbiased clinical trials, and there
would be no use for advertising. In this world, physicians would simply
prescribe the best drug. So why does this model not work in the real world?
To a large degree it is because the U.S. Food and Drug Administration
(FDA) typically does not require new drugs to be tested against existing
treatments. Instead, it requires only that they be tested against placebos. 
15
This is an easier benchmark to meet, as it merely requires that the new
drug be effective, but not necessarily better than standard therapy. Drug
companies, however, have little financial incentive for head-to-head trials
with other effective therapies if they are not required for FDA approval
and if one company stands to lose the contest. Thus the controlled trials
needed to decide the best therapy are often never performed.
While she argues powerfully, Katharine Greider's credentials, as well as
her scholarship, are skimpy at best. Her terse biosketch on the book cover
describes her as a newspaper reporter and free-lance magazine writer with
articles focusing on health and medical topics. She lists no footnotes or
references anywhere in her book, and her sources are listed in a brief two-
page description at the very end. Her book, which runs a mere 180 pages,
is published by PublicAffairs, a notable source of alternative and self-
acknowledged gadfly journalism.
In contrast, Daniel Vasella, as chairman and chief executive officer of
Novartis, one of the largest pharmaceutical companies in the world, has
clear-cut qualifications as a business leader in the pharmaceutical industry.
He also has a potentially very exciting story to tell in his book, Magic Cancer
Bullet, published by HarperBusiness. As the subtitle of the book claims, this
book sets out to recount "how a tiny orange pill is rewriting medical
history." He provides his personal perspective on the development of the
first anticancer therapy which is targeted to a specific molecular lesion.
The drug is imatinib (trade name Gleevec), and the disease it treats is
chronic myelogenous leiukemia (CML). Imatinib is the first commercially
14. See David L. Sackett et al., Evidence Based Medicine: What It Is and What It Isn't, 312
BRIT. MED.J. 71 (1996).
15. Marcia Angell, The Pharmaceutical Industiy - To Whom Is It Accountable?, 342 NEW
ENG.J. MED. 1902 (2000).
IV:I1 (2004)
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available "molecular" therapy for cancer, and it is designed to inhibit the
kinase function of the mutant fusion protein Bcr-Abl that drives the
myeloproliferative process underlying the pathogenesis of CML.1
6
Vasella's book is largely a narrative of Novartis's involvement in the
initial clinical testing of imatinib, an account sprinkled with vignettes
about some of the first patients to take the drug. He devotes relatively little
time or credit to the years of NIH-funded academic research that made the
development of imatinib, and indeed most other modern pharmaceuticals,
possible." He describes a number of key scientists in the company who
oversaw the synthesis of the compound and the early clinical trials, as well
as the anxiety they experienced manufacturing enough of the drug for the
anticipated need and monitoring the early reports of clinical testing.
Those early trials were dramatically positive, with a large majority of
patients with CML showing excellent responses to imatinib, which is a
simple oral medication with relatively few side effects. 8 Based on those
initial studies, the FDA rapidly approved imatinib for the treatment of
CML, and it is now the standard therapy for the stable phase of the
disease."
This book is primarily intended to be a "good news" story for patients
with leukemia and their families, and not a treatise on public health policy
toward the pharmaceutical industry. Nonetheless, Dr. Vasella presents this
success story as evidence that large drug companies, driven by the profit
motive, are the best hope for the development of effective new therapies.
He invokes a business model he calls "innovation management," a model
that "assumes that the private sector is the most capable of carrying out
innovative drug discoveries., 20 This premise is a little difficult to accept in
the case of imatinib, given the pioneering work of numerous academic
researchers that led to imatinib's discovery. His arguments for free
enterprise, scattered throughout the narrative, are simplistic and under-
developed: "We must be able to protect our patents for drugs; otherwise
there will be no incentive for our scientists to be innovative .... And we
must structure our prices high enough to assure a return on investment
16. SeeVASELLA WITH SLATER, supra note 3, at 27.
17. Jeff Gerth & Sheryl G. Stolberg, Drug Makers Reap Profits on Tax-Backed Research, N.Y.
TIMES, April 23, 2000, at Al.
18. BrianJ. Druker et al., Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine
Kinase in Chronic Myeloid Leukemia, 344 NEw ENG.J. MED. 1031-32. (2001).
19. For a discussion of imatinib's FDA approval process, see VASELLA WITH SLATER, supra
note 3, at 137-67.
20. VASELLA WITH SLATER, supra note 3, at 92.
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sufficient to support ongoing research and development. '
Dr. Vasella believes that Novartis took enormous risks to develop
imatinib. Unfortunately, however, his view is not well supported by the
facts. The effectiveness of imatinib in preclinical tests in cell lines2 and
mouse models 23 of CML was impressive, early clinical trials went very
smoothly, and FDA approval took a record-setting two and a half months.
He repeatedly sounds the message that he continued to push for the
drug's development, even though he feared the market for it would be too
small to make a profit for Novartis, because he thought it was in the best
interest of the patients. 24 While these are noble sentiments, they ring a little
false when one recognizes that imatinib has significant activity in three
other rare malignancies-gastrointestinal stromal tumors (or GISTs) ,5
hypereosinophilic syndrome, 2  and certain forms of chronic
myelomonocytic leukemia, 27 and is now being tested in a variety of
common tumors, such as prostate cancer.2" Gleevec has also helped
establish Novartis as one of the premier oncology franchises leading the
targeted therapy drive of the future. So Gleevec may yet make money for
Novartis.
The last chapter of the book, cleverly entitled "Success Management,"
is largely devoted to justifying the pricing and patent practices of the
pharmaceutical industry. Vasella talks in fair detail about the pricing issues
for Gleevec, citing an unreferenced claim that the average cost of research
and development for a new drug is about $880,000,000. 9 Other authors
have put the figure closer to $500,000,000. 30 He provides no figures for the
21. Id. at 18.
22. Brian J. Druker et al., Effects of a Selective Inhibitor of the Ab Tyrosine Kinase on the
Growth of Bcr-Abl Positive Cells, 2 NATURE MED. 561 (1996).
23. Nicholas C. Wolff & Robert L. Ilaria, Jr., Establishment of a Murine Model for Therapy-
Treated Chronic Myelogenous Leukemia Using the Tyrosine Kinase Inhibitor STI5 71, 98 BLOOD
2808 (2001).
24. See, e.g., VASELLA WITH SLATER, supra note 3, at 15-16.
25. HeikkiJoensuu et al., Management of Malignant Gastrointestinal Stroma Tumours, 3
LANCET ONCOLOGY 655 (2002).
26. Jan Cools et al., A Tyrosine Kinase Created by Fusion of the PDGFRA and FIPiLI Genes as
a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome, 348 NEw ENGLANDJ.
MED. 1201 (2003).
27. Magnus K. Magnusson et al., Activity of STI571 in Chronic Myelomonocytic Leukemia with
a Platelet-Derived Growth Factor Beta Receptor Fusion Oncogene, 100 BLOOD 1088 (2002).
28. VASELLA WITH SLATER, supra note 3, at 27-28.
29. VASELLA wITH SLATER, supra note 3, at 175.
30. Davidoff, supra note 4.
IV:l1 (2004)
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research and development dollars expended by Novartis to develop
imatinib itself, and states that they based their pricing for Gleevec
($2,200/month) on the cost of alpha interferon, another standard drug
used to treat CML . My Veterans Affairs hospital pays $1,432 for a month's
supply of imatinib; by comparison, hydroxyurea, another oral medication
used to control CML, costs less than $20/month. Vasella quite correctly
points out the inequities in Medicare reimbursement that preclude
payment for oral cancer drugs and force many elderly patients with CML
to pay for their medication out of their own pockets.3 3 This Medicare policy
will seem increasingly dated as more molecular therapies are introduced,
replacing toxic intravenous medications with simpler oral therapies with
fewer side effects. While Vasella and Novartis should be applauded for
initiating a patient support program for those individuals who cannot
afford the medication,34 several other pharmaceutical companies already• • 35
have similar policies for expensive cancer medications.
Reading these two books back to back is reminiscent of the old saw
about the statistician who would say that a person with one foot in a bucket
of ice water and the other foot in a bucket of boiling water was, on average,
comfortable. Read together the books do not provide a balanced
perspective on the problems of the pharmaceutical industry, nor any
guidance as to how change could best be effected. As of this writing,
President Bush had just signed a Medicare prescription drug benefit into
law, but its value to consumers is delayed and remains uncertain. Until
there is an effective national health policy for prescription drugs, the
licensed health care providers who can prescribe expensive life-saving
medications represent the most effective agents for near-term change.
These providers need to find the will to 1) pressure drug companies to
31. VASELLA WITH SLATER, supra note 3, at 179.
32. Information regarding spending at the author's Veterans Affairs hospital is on file




33. VASELLA WITH SLATER, supra note 3, at 126.
34. Id. at 179.
35. For a list of other pharmaceutical companies providing such programs, see Indigent
Patient Programs, The Nutrition Advisor, at
http://www. nutritionadvisor com/indigent. htm ?source=overture#research (last visited Jan. 16,
2004).
36. Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L.
No. 108-173, 117 Stat. 2066.
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reduce or eliminate Direct-To-Consumer advertising, 2) resist the
aggressive marketing practices directed at them, 3) use evidence-based
medicine wherever possible to assure more cost-effective (and cost-saving)
prescribing, and 4) press Congress to pass legislation requiring
comparative drug trials before FDA licensing.
If marketing practices are to be reduced substantially, those marketing
practices must be made to fail. For health care professionals who need
more moral support to take on these challenges, they would do well to go
to the website of the non-profit group No Free Lunch,3M a devoted group of
physicians endeavoring to limit the influence of pharmaceutical marketing
on prescribing practices. At that website, physicians and medical students
can get concrete suggestions on actions they can take to aid in that
endeavor and are invited to take the following public pledge: "I... pledge
to accept no money, gifts, or hospitality from the pharmaceutical industry;
to seek unbiased sources of information and not rely on information
disseminated by drug companies; and to avoid conflicts of interest in my
practice, teaching, and/or research. '39 Neither Greider nor Vasella discuss
the important role that physicians could play in the near term in creating
change in pharmaceutical pricing. To paraphrase the closing comment in
Greider's book, if the perspective of a large drug company is "Who is going
to stop me.F'40 physicians must say "We will."
37. Angell, supra note 15.
38. Just Say No to Drug Reps, No Free Lunch, at http://www.nofreelunch.org/ (last
visited Jan. 6, 2004). The website invites readers to protest drug-company sponsored meals
to their Department Chairs and/or Program Directors and to give talks on the subject of
drug-company influence on prescribing practices, using slide show presentations created by
No Free Lunch. What Can You Do?, No Free Lunch, at
http://www.nofreelunch.org/todo.htm (last visitedJan. 6, 2004).
39. Take the Pledge, No Free Lunch, at https://ironclad.secure-
orders.net/nofreelu/pledge.htm (last visitedJan. 6, 2004).
40. GREIDER, supra note' 1, at 174.
IV: 1 (2004)
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